Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
PaperCitations, authors & open-access status
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 393 citations, 2019 year and bronze oa status.
393
Citations
2019
Year
bronze
OA Status